BRAF and melanoma: Due to their rare nature and exclusion from larger drug approval studies, fewer data exist on the efficacy of BRAF inhibition and/or MEK inhibition in less frequent BRAF mutants, which account for approximately 3.4–14% of BRAF-mutated melanomas [2, 5•, 8, 11–12].